Affiliations 

  • 1 Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan
PLoS Negl Trop Dis, 2012;6(2):e1536.
PMID: 22389741 DOI: 10.1371/journal.pntd.0001536

Abstract

Progress in dengue vaccine development has been hampered by limited understanding of protective immunity against dengue virus infection. Conventional neutralizing antibody titration assays that use FcγR-negative cells do not consider possible infection-enhancement activity. We reasoned that as FcγR-expressing cells are the major target cells of dengue virus, neutralizing antibody titration assays using FcγR-expressing cells that determine the sum of neutralizing and infection-enhancing activity, may better reflect the biological properties of antibodies in vivo.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.